$NRIX
Nurix Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000154959523000048 Filed on October 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $15.16M $18.47M
YoY Change 123.49% 71.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.78M $10.62M
YoY Change 15.08% 8.95%
% of Gross Profit
Research & Development $49.71M $47.86M
YoY Change 7.82% 0.2%
% of Gross Profit
Depreciation & Amortization $1.933M $1.950M
YoY Change 19.39% 33.84%
% of Gross Profit
Operating Expenses $60.49M $58.48M
YoY Change 9.05% 1.69%
Operating Profit -$40.01M
YoY Change -14.35%
Interest Expense $3.378M $3.030M
YoY Change 71.21% 200.3%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$41.96M -$36.98M
YoY Change -10.19% -19.1%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$41.96M -$36.98M
YoY Change -10.19% -19.09%
Net Earnings / Revenue -276.77% -200.26%
Basic Earnings Per Share -$0.68
Diluted Earnings Per Share -$0.77 -$0.68
COMMON SHARES
Basic Shares Outstanding 48.50M shares 54.39M shares
Diluted Shares Outstanding 54.39M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $287.9M $258.9M
YoY Change -6.6% -24.84%
Cash & Equivalents $54.63M $42.30M
Short-Term Investments $233.3M $216.5M
Other Short-Term Assets $7.595M $7.100M
YoY Change -25.6% -31.68%
Inventory
Prepaid Expenses
Receivables $2.000M
Other Receivables $0.00
Total Short-Term Assets $295.5M $267.9M
YoY Change -7.21% -24.49%
LONG-TERM ASSETS
Property, Plant & Equipment $16.81M $16.58M
YoY Change -2.07% 0.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $7.421M $9.900M
YoY Change -88.38% -85.68%
Other Assets $3.823M $3.855M
YoY Change -4.95% -5.79%
Total Long-Term Assets $60.10M $40.25M
YoY Change -38.87% -61.47%
TOTAL ASSETS
Total Short-Term Assets $295.5M $267.9M
Total Long-Term Assets $60.10M $40.25M
Total Assets $355.6M $308.2M
YoY Change -14.68% -32.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.401M $2.187M
YoY Change 26.4% -63.87%
Accrued Expenses $32.46M $27.30M
YoY Change 16.1% 8.74%
Deferred Revenue $48.10M $32.04M
YoY Change 27.81% -11.85%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $86.96M $61.49M
YoY Change 23.07% -8.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $68.15M $12.90M
YoY Change 60.69% -73.83%
Total Long-Term Liabilities $68.15M $12.90M
YoY Change 60.69% -73.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $86.96M $61.49M
Total Long-Term Liabilities $68.15M $12.90M
Total Liabilities $155.1M $74.38M
YoY Change 37.18% -36.32%
SHAREHOLDERS EQUITY
Retained Earnings -$545.2M -$503.2M
YoY Change 35.86% 41.95%
Common Stock $746.3M $738.3M
YoY Change 5.23% 5.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $200.5M $233.8M
YoY Change
Total Liabilities & Shareholders Equity $355.6M $308.2M
YoY Change -14.68% -32.9%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$41.96M -$36.98M
YoY Change -10.19% -19.09%
Depreciation, Depletion And Amortization $1.933M $1.950M
YoY Change 19.39% 33.84%
Cash From Operating Activities $26.69M -$41.13M
YoY Change -170.31% -11.18%
INVESTING ACTIVITIES
Capital Expenditures $2.581M $2.460M
YoY Change 0.62% -171.97%
Acquisitions
YoY Change
Other Investing Activities -$11.79M $25.23M
YoY Change -120.47% -142.29%
Cash From Investing Activities -$14.37M $22.77M
YoY Change -126.12% -136.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.000K 1.700M
YoY Change -105.19% -98.53%
NET CHANGE
Cash From Operating Activities 26.69M -41.13M
Cash From Investing Activities -14.37M 22.77M
Cash From Financing Activities 7.000K 1.700M
Net Change In Cash 12.32M -16.66M
YoY Change -27.16% -376.61%
FREE CASH FLOW
Cash From Operating Activities $26.69M -$41.13M
Capital Expenditures $2.581M $2.460M
Free Cash Flow $24.10M -$43.59M
YoY Change -159.49% 1.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
216548000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
244667000 usd
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Revenues
Revenues
18467000 usd
CY2022Q3 us-gaap Revenues
Revenues
10791000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36982000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45709000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
675000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-657000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46366000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7097000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9308000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
267949000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
318449000 usd
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
9882000 usd
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
63879000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9027000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12345000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16581000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17163000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3855000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4022000 usd
CY2023Q3 us-gaap Assets
Assets
308195000 usd
CY2022Q4 us-gaap Assets
Assets
416759000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2187000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5064000 usd
CY2023Q3 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21907000 usd
CY2022Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
22428000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5362000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5530000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
32037000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
37633000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
61493000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70655000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2642000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6434000 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
10243000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
35974000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
74378000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
113063000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47172299 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47172299 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
49000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
47000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
738240000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
709220000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1228000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4319000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-503244000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401252000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
233817000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
303696000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
308195000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
416759000 usd
us-gaap Revenues
Revenues
61828000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
138391000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32122000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28630000 usd
us-gaap Operating Expenses
OperatingExpenses
171557000 usd
us-gaap Operating Expenses
OperatingExpenses
167021000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-109729000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-135177000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
7737000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
1534000 usd
us-gaap Net Income Loss
NetIncomeLoss
-133643000 usd
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54390859 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54390859 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50868542 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50868542 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54227491 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54227491 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46835776 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46835776 shares
us-gaap Net Income Loss
NetIncomeLoss
-101992000 usd
us-gaap Net Income Loss
NetIncomeLoss
-133643000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3091000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3134000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36307000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98901000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-136777000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
424000 usd
CY2022Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
47000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1064000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6071000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1458000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-42533000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
305917000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
432000 usd
CY2022Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
35000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6775000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1019000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-45401000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
266739000 usd
CY2022Q3 nrix Adjustments To Additional Paid In Capital Pre Funded Warrants Issuance Costs
AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuanceCosts
234000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
94759000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19328000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000 usd
CY2022Q3 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
32000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
891000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6988000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-657000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45709000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
342545000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
303696000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000 usd
CY2023Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
31000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1453000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8505000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1072000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40733000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
274052000 usd
CY2023Q2 nrix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000 usd
CY2023Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
31000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8746000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1344000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24277000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
259921000 usd
CY2023Q3 nrix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
927000 usd
CY2023Q3 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
29000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
776000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8470000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
675000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36982000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
233817000 usd
us-gaap Net Income Loss
NetIncomeLoss
-101992000 usd
us-gaap Net Income Loss
NetIncomeLoss
-133643000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5599000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3730000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
25649000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
19834000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3453000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1076000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-544000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4298000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4041000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-201000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2556000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2250000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3036000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
984000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31327000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-22344000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4940000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3679000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
48000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
4189000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108054000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-121852000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
157941000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
212455000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
246431000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
194324000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5816000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9679000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
82674000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27810000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
94942000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19400000 usd
nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
981000 usd
nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
1030000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2229000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1955000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3210000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117327000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22170000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32335000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65375000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43205000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48457000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1054000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1726000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
72000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 usd
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
91000 usd
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
114000 usd
nrix Issuance Costs Related To Pre Funded Warrants Included In Accrued Expenses And Other Liabilities
IssuanceCostsRelatedToPreFundedWarrantsIncludedInAccruedExpensesAndOtherLiabilities
0 usd
nrix Issuance Costs Related To Pre Funded Warrants Included In Accrued Expenses And Other Liabilities
IssuanceCostsRelatedToPreFundedWarrantsIncludedInAccruedExpensesAndOtherLiabilities
183000 usd
nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
0 usd
nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
72000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42304000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47556000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43205000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48457000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
258900000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-503200000 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Refer to Note 3 for more information regarding the estimates related to revenue recognition.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company invests its cash equivalents in highly rated money market funds. The Company’s marketable securities consist of debt securities issued by highly rated corporate entities, foreign governments, the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy, and its ongoing cash management strategy is to maintain diversity in its deposit accounts across financial institutions; however, the Company is exposed to credit risk on deposits in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, including Silicon Valley Bank (SVB). As of March 27, 2023, in connection with the closure of SVB by the California Department of Financial Protection and Innovation and the FDIC, First-Citizens Bank & Trust Company assumed all of SVB’s deposits and loans. Prior to SVB’s closure, the Company maintained with SVB an operating account with a cash balance of less than 1% of the Company’s total cash, cash equivalents and marketable securities. In light of the foregoing, the Company does not believe that it has exposure to loss as a result of SVB’s receivership. During the periods presented, the Company has not experienced any realized losses on its deposits of cash, cash equivalents or marketable securities.
CY2023Q3 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21907000 usd
CY2022Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
22428000 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
41627000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36833000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25046000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19670000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16581000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17163000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11534000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13164000 usd
CY2023Q3 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
7955000 usd
CY2022Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
6426000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1550000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1250000 usd
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
34000 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
85000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
834000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1503000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 security
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 security
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2023Q3 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2023Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
57902 sqft
CY2021Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
19320 sqft
nrix Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
2 terms
CY2022Q1 nrix Lessee Operating Lease Liability To Be Paid Year One Per Month
LesseeOperatingLeaseLiabilityToBePaidYearOnePerMonth
154000 usd
CY2022Q1 nrix Operating Lease Rent Payable Per Month
OperatingLeaseRentPayablePerMonth
211000 usd
CY2022Q1 nrix Percentage Of Increase Of Annual Rent
PercentageOfIncreaseOfAnnualRent
0.03
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
4500000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
4400000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
4182000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
5198000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5060000 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19043659 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18016515 shares
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
62800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000 usd
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1000000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36982000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45709000 usd
us-gaap Net Income Loss
NetIncomeLoss
-101992000 usd
us-gaap Net Income Loss
NetIncomeLoss
-133643000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54390859 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54390859 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50868542 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50868542 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54227491 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54227491 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46835776 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46835776 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10132980 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9019337 shares

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001549595-23-000048-index-headers.html Edgar Link pending
0001549595-23-000048-index.html Edgar Link pending
0001549595-23-000048.txt Edgar Link pending
0001549595-23-000048-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrix-20230831.htm Edgar Link pending
nrix-20230831.xsd Edgar Link pending
nrix-20230831xex101.htm Edgar Link pending
nrix-20230831xex102.htm Edgar Link pending
nrix-20230831xex103.htm Edgar Link pending
nrix-20230831xex311.htm Edgar Link pending
nrix-20230831xex312.htm Edgar Link pending
nrix-20230831xex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
nrix-20230831_cal.xml Edgar Link unprocessable
nrix-20230831_lab.xml Edgar Link unprocessable
nrix-20230831_def.xml Edgar Link unprocessable
nrix-20230831_pre.xml Edgar Link unprocessable
nrix-20230831_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending